AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00511329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: somatropin [rDNA origin] for injection
Description: Genotropin will be started at 0.3 mg/kg/week administered by daily subcutaneous injection. Doses will be increased by weight at each visit. Additionally, we will monitor IGF-1 levels at month 3, and 6 and adjust the Genotropin dose to maintain IGF-1 levels in the 50th -75th percentile for ages.
Study NCT02080273 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Colgate Cavity Protection toothpaste
Description: 0.76% monofluorophosphate (1000 ppm MFP), Colgate Cavity Protection toothpaste is a control treatment.
Study NCT02080273 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colgate Total toothpaste
Description: 0.32% sodium fluoride (1450 ppm NaF) and 0.3% triclosan. Colgate Total toothpaste is the active comparator toothpaste
Study NCT02080273 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Parodontax toothpaste
Description: 1400 ppm sodium fluoride (NaF), Parodontax toothpaste is the active comparator toothpaste
Study NCT02534610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoricoxib
Description: 120 mg etoricoxib PO administered 1 h preoperative for group A; group B received 120 mg etoricoxib PO at the end of the surgery.
Study NCT02534610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Group A received 1 sham pill PO at the end of the surgery; group B received 1 sham pill PO 1 h preoperative and group C received sham pill PO 1 h preoperative and 1 sham pill PO at the end of the surgery.
Study NCT02534610 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Group A received 1 sham pill PO at the end of the surgery; group B received 1 sham pill PO 1 h preoperative and group C received sham pill PO 1 h preoperative and 1 sham pill PO at the end of the surgery.
Study NCT03065881 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RETeval
Description: The RETeval device measures the retina's electrical response to light, called an electroretinogram (ERG). The standards body ISCEV \[1\] recommends collecting normative data for ERGs to provide waveforms and statistically relevant measurements representing the range of ERGs from people with normal vision. LKC Technologies provides this information with their UTAS product line and wishes to collect such a database for the newest device: the RETeval device. As the RETeval device uses a different electrode to measure the ERG, the normal data for the UTAS product line is not transferable to the RETeval device. Ophthalmic practitioners would also like ERG examples of specific retinal disorders to help diagnose patients with abnormal ERGs. The RETeval device is FDA cleared (K142567),
Study NCT04089267 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPO
Study NCT03126799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib plus Bevacizumab
Description: Erlotinib 150mg, po, daily, q 3weeks plus Bevacizumab 15mg/kg, IV, on D1 Q 3 weeks
Study NCT03109613 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Positive end-expiratory pressure (PEEP)
Description: level changes as per arm description
Study NCT03126799 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erlotinib
Description: Erlotinib 150mg, po, daily, Q weeks
Study NCT02845661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: a bolus of dexmedetomidine was administered intravenously 15 min after spinal anesthesia,and the initial dose in group 1 was started from 0.9 µg/kg
Study NCT02845661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: a bolus of dexmedetomidine was administered intravenously 15 min after spinal anesthesia,and the initial dose in group 2 was started from 1.0 µg/kg
Study NCT02845661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: a bolus of dexmedetomidine was administered intravenously 15 min after spinal anesthesia,and the initial dose in group 3 was started from 1.1 µg/kg
Study NCT04106791 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: closed-loop system for vasopressor administration
Description: The closed-loop system' goal is to keep MAP within 5 mmHg of the predefined target MAP.
Study NCT02199418 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Study NCT02199418 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Study NCT00876317 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoricoxib 60 mg
Description: Etoricoxib 60 mg per oz per day for 14 days
Study NCT00876317 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoricoxib 90 mg
Description: Etoricoxib 90 mg per oz for 14 days
Study NCT02645994 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Target Controlled Infusion
Description: Used to control intravenous propofol delivery with target plasma concentratioins changed manually
Study NCT02645994 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Closed Loop Anesthesia Delivery System
Description: Used to deliver propofol automatically titrated to achieve a target BIS 50, and maintain it between 40 and 60.
Study NCT00594256 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Oxybate
Description: Patients will undergo a one-week evaluation period, which will include a taper and discontinuation of any currently prescribed sedative/hypnotics, as well as baseline diagnostic, psychopathology, neurocognitive and polysomnographic measurements (see below for details). Hypnotic taper may be extended or abbreviated, depending on clinical judgment. Patients will then begin a 4-week trial of adjunctive Xyrem (sodium oxybate). Patients will begin at 4.5 g/night (in divided doses of 2.25 g, with 1st dose at bedtime and then 2nd dose four hours later). Dosage will increase by 1.5 g/day every week, until a dose of 9 g nightly is reached, or a patient cannot tolerate further dose escalations. Medication will be administered in divided dosage for the duration of the study. A three-week taper (by 3 g/day weekly) of sodium oxybate will follow the four-week trial of sodium oxybate.
Study NCT01867034 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Drug Eluting Stent
Description: Comparison of two stents to see which results in best outcome.
Study NCT01867034 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bare Metal Stent
Study NCT01205724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: turoctocog alfa pegol
Description: Single dose (low) administered intravenously (into the vein)
Study NCT01205724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: turoctocog alfa pegol
Description: Single dose (medium) administered intravenously (into the vein)
Study NCT01205724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: turoctocog alfa pegol
Description: Single dose (high) administered intravenously (into the vein)
Study NCT03454438 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Referral strategies
Description: Two referral strategies will be compared to usual care, i.e. the control group. Patients will be followed for one year.
Study NCT02147808 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telotristat etiprate
Description: All subjects will receive two 250 mg telotristat etiprate tablets three times daily.
Study NCT02147808 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: All subjects will receive 3 mg (1.5 mL oral syrup \[2mg/mL\]).
Study NCT03162276 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Inquiry Based Stress Reduction (IBSR) program
Description: The IBSR (Inquiry-based stress reduction) intervention, developed by Byron Katie, trains participants to reduce their perceived level of stress by self-inquiry of their thoughts and beliefs connected to stressful circumstances or symptoms. This meditative process, named The Work, enables the participants to identify and question the stressful thoughts that cause their suffering. The core of IBSR is simply four questions and a turnaround, which is a way of experiencing the opposite of what the participant believes. This process is simple, powerful and provides skills for self-inquiry and management of stressful thoughts that can be easily implemented in daily life
Study NCT03162276 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: At end of intervention, the control group will receive a brief intervention consisting of a home kit for practicing IBSR techniques.
Study NCT04160260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omadacycline
Description: Omadacycline: PO Tablets
Study NCT04341038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: the necessary dose to obtain blood levels of 8-10 ng / ml
Study NCT04341038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: 120mg of methylprednisolone daily for 3 consecutive days
Study NCT03113591 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Minimum invasive total hip arthroplasty
Description: Minimum invasive total hip arthroplasty using the osteo introducer system
Study NCT01015456 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate sodium
Description: per oral, twice daily, for 12 months
Study NCT03113591 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Common total hip arthroplasty
Description: Common total hip arthroplasty using common instruments
Study NCT01015456 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Description: intravenous, monthly, for 6 months
Study NCT02960984 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Task Oriented rehabilitation and aerobic training
Description: Participants in the experimental group will receive 1 hour treatment comprising 30' of aerobic training and 30' of task-oriented training focused on uppper limb rehabilitation for 3 times a week for 20 sessions.
Study NCT04074122 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Adenosine and epinephrine, isoprenaline provocation
Description: High-resolution electromechanical mapping at baseline and after provocative measures.
Study NCT01352520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGN-35
Description: 1.8 mg/kg administered by outpatient IV infusion given over approximately 30 minutes on Day 1 of each 21-day cycle.
Study NCT03837496 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: STRIDE
Description: STRIDE is a brief, group-based, virtual (videoconference) cognitive-behavioral intervention. The intervention incorporates adherence problem-solving, cognitive restructuring, relaxation training, symptom management, coping skills training, and mindfulness techniques.
Study NCT03837496 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medication Monitoring Control
Description: Care provided as standard by the hospital and medication monitoring
Study NCT00448058 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK372475
Description: daily administration during the 10-week treatment phase
Study NCT00448058 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: venlafaxine
Description: daily administration during the 10-week treatment phase
Study NCT00448058 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: daily administration during the 10-week treatment phase
Study NCT01115426 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ramipril or losartan
Description: Ramipril (5 mg/day) was started soon after the enrollment and continued throughout the follow-up, having Losartan (50 mg/day) as alternative.
Study NCT03728803 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Threshold IMT, Philips Respironics, Murrysville, PA, USA
Description: Active inspiratory muscle training (IMT) by the threshold IMT provides consistent and specific pressure for inspiratory muscle strength and endurance training, regardless of how quickly or slowly patients breathe. This device incorporates a flow-independent one-way valve to ensure consistent resistance and features an adjustable specific pressure setting (in cmH20) to be set. When patients inhale through the Threshold IMT, a spring-loaded valve provides a resistance that exercises respiratory muscles through conditioning.
Study NCT03728803 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Threshold IMT, Philips Respironics, Murrysville, PA, USA
Description: Active inspiratory muscle training (IMT) by the threshold IMT provides consistent and specific pressure for inspiratory muscle strength and endurance training, regardless of how quickly or slowly patients breathe. This device incorporates a flow-independent one-way valve to ensure consistent resistance and features an adjustable specific pressure setting (in cmH20) to be set. When patients inhale through the Threshold IMT, a spring-loaded valve provides a resistance that exercises respiratory muscles through conditioning.
Study NCT02598349 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton Radiation
Description: Proton Radiation 40.50 Gy relative biological effectiveness (RBE) in 18 fractions to gross disease and elective nodal volume followed by a 22.50 Gy (RBE) in 10 fraction boost to gross disease. Total dose 63 Gy (RBE) in 28 fractions over 6 weeks.
Study NCT02598349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Concomitant oral chemotherapy, capecitabine 1000mg by mouth twice daily, 5 days a week (M-F) on radiation days only.
Study NCT02598349 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical resection
Description: Surgery between 8 and 16 weeks of radiotherapy completion if radiographic studies suggest operability.
Study NCT01999010 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MHT
Description: MHT and visualizer contains mood information about the patient themselves, which allows for self management of the mood disorder. Self-management interventions promote early recognition of mood episodes, medication adherence and self-management skills which have shown to improve outcomes in depression. MHT encourages patients to take an active role by engaging in mood journaling, while making this information available in explorable form to the patient and his / her team of clinicians.
Study NCT02803697 — intervention group
Intervention type: OTHER
Intervention: Patients
Study NCT03300245 — intervention group
Intervention type: RADIATION
Intervention: Maxillofacial CT
Description: clinical and maxillofacial CT data will be tabulated and analysed using by computer software e.g. Statistical Package for the Social Sciences (SPSS)
Study NCT01338116 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: antibiotic treatment of by TREAT/PCR
Description: Management by TREAT/PCR. The data available at the time of patient recruitment will be entered into TREAT. TREAT will provide advice for the empirical antibiotic treatment and unless the caring physician can justify a deviation from this recommendation, TREAT's recommendation will be implemented (yes or no antibiotic treatment and type of antibiotic). TREAT will also recommend whether a blood sample for PCR should be obtained. Blood will be collected aseptically and the test will be performed once daily between 1000AM-1700PM (results available daily at 1700 PM). PCR results and a PCR-revised TREAT recommendation will be reported to the patient's physician in charge and treatment will be revised accordingly. On day 2, when results of blood cultures and other cultures become available TREAT will be re-consulted and will issue a new recommendation based on the full microbiological investigation (negative and positive results).
Study NCT00536367 — intervention group
Intervention type: OTHER
Intervention: No intervention - observational study only
Study NCT00128258 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Injection of bone marrow cells in the heart
Description: Biological implant into the heart
Study NCT00128258 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biological bone marrow cell therapy
Description: Biological implant into the heart
Study NCT02653677 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: intake of the specific kind of bread
Description: To determine the glycemic and insulinemic responses (area-under the curve, AUCs), the satiety rate and the AUCs of free fatty acids (FFA), triglycerides and ghrelin after the ingestion of four types of breads, each containing 50g of available carbohydrates
Study NCT02653677 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: intake of the specific kind of bread
Description: To determine the glycemic and insulinemic responses (area-under the curve, AUCs), the satiety rate and the AUCs of free fatty acids (FFA), triglycerides and ghrelin after the ingestion of four types of breads, each containing 50g of available carbohydrates
Study NCT02490137 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Race Car Video Game
Description: Repeatedly playing a race car video game
Study NCT03191903 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Cingal
Description: Hyaluronic Acid with Triamcinolone Hexacetonide
Study NCT03191903 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Monovisc
Description: Hyaluronic acid
Study NCT03191903 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Hexacetonide
Description: Triamcinolone Hexacetonide
Study NCT02791815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Single oral dose of 7.5 mg midazolam (tablet)
Study NCT02791815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selexipag
Description: Oral administration of selexipag (200 µg film-coated tablet) for 12 consecutive days (with a titration scheme from 400 to 1600 μg b.i.d. )
Study NCT03224234 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insulclock with feedback
Description: Daily information on a smartphone on insulin administration (time and dosing) as well as reminders in the event of missing doses.
Study NCT03224234 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Insulclock without feedback
Description: Not feedback on insulin administration.
Study NCT01328002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milnacipran
Description: Maximum tolerated dose (50, 75, or 100 mg/day tablets) was determined during the open label phase of the study.~Oral administration, twice daily dosing
Study NCT01328002 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo tablets daily
Study NCT00813761 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: O2Optix contact lens
Description: control contact lens to be worn daily for approximately 7 months for entire length of study.
Study NCT00813761 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Proclear contact lens
Description: control contact lens to be worn for entire length of study.
Study NCT00813761 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: ReNu MultiPlus Multi-Purpose Solution
Description: lens solution for overnight lens disinfection
Study NCT00813761 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Clear Care Cleaning and Disinfecting Solution
Description: lens solution for overnight lens disinfection
Study NCT00452881 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gemcitabine
Description: Gemcitabine1250mg/m2 iv on day 1 and 15, every 4weeks, maximum 4 cycles
Study NCT00452881 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: Gemcitabine1250mg/m2 iv on day 1 and 15, every 4weeks, maximum 4 cycles
Study NCT00452881 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin 85mg/m2 iv on day 1 and 15, every 4 weeks, maximum 4 cycles
Study NCT00452881 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin 40mg/m2 iv on day 1 and 15, every 4 weeks, maximum 4 cycles
Study NCT04229862 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway insertion
Description: Laryngeal mask airway insertion in patients who undergoing transurethral bladder tumor resection
Study NCT04229862 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laryngeal mask airway insertion
Description: Laryngeal mask airway insertion in patients who undergoing transurethral bladder tumor resection
Study NCT03194542 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Luspatercept
Description: Luspatercept is a recombinant fusion protein consisting of a modified form of the extracellular domain of the human active in receptor type IIB linked to the IgG1 Fc domain. Luspatercept, through a mechanism of action different from erythropoietin, works to correct ineffective erythropoiesis by promoting late-stage maturation of erythroblasts.
Study NCT03989102 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ Vaccine
Description: PfSPZ vaccine is comprised of aseptic, metabolically active, non-replicating, purified, cryopreserved P. falciparum sporozoites.
Study NCT01222585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Description: Metronidazole will be administered intravenously to premature infants as a 15 mg/kg loading dose followed by maintenance doses of 7.5 mg/kg every 12 hours for infants with >=14 postnatal days and every 24 hours for infants \<14 postnatal days.
Study NCT01443442 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bepotastine besilate, 1.5%
Description: Topical ocular aqueous formulation, oen drop per instillation, twice per day for 14 days